The SLIT family of genes consists of large extracellular matrix-secreted and membrane-associated glycoproteins. The Slits (Slit1-3) are ligands for the repulsive guidance receptors, the robo gene family. The Slit-Robo interactions mediate the repulsive cues on axons and growth cones during neural development. In a recent report, we demonstrated that promoter region CpG island of human SLIT2 was frequently hypermethylated in lung, breast and colorectal tumours and the silenced gene transcript suppressed the malignant phenotype in in vitro assays. In this report we undertook epigenetic, genetic and expression analysis of SLIT2 gene in a large series of gliomas and glioma cell lines. Promoter region CpG island of SLIT2 was found to be methylated in 71% (5/7) of glioma cell lines and was unmethylated in five DNA samples from normal brain tissues. The hypermethylation of the SLIT2 promoter region in glioma cell lines correlated with loss of expression and treatment with the demethylating agent 5-aza-2'-deoxycytidine reactivated SLIT2 gene expression. In primary gliomas, SLIT2 was methylated in 59% (37/63) of tumours analysed. In addition, SLIT2 expression was downregulated in methylated gliomas relative to unmethylated tumour samples, as demonstrated by quantitative real-time RT-PCR. Loss of heterozygosity analysis revealed that SLIT2 methylated gliomas retained both alleles of a microsatellite marker within 100 kb of the SLIT2 gene at 4p15.2. Exogenous expression of SLIT2 in a glioma cell line that was heavily methylated for SLIT2 decreased in vitro colony formation. Our data indicate that SLIT2 is frequently inactivated by promoter region CpG island hypermethylation in gliomas and may be a good candidate for a glioma tumour suppressor gene (TSG) located at 4p15.2. Furthermore, our data suggest that a detailed analysis of both the cancer genome and epigenome will be required to identify key TSGs involved in glioma development.
Introduction
Human gliomas represent a heterogeneous group of primary brain tumours that may be subdivided into four grades on the basis of their histology and prognosis. Most gliomas are sporadic and familial cases are uncommon. Malignant gliomas are classified as astrocytomas, oligodendrogliomas and oligoastrocytomas. Patients with the most malignant grade 4 gliomas, also referred to as glioblastoma multiforme (GBM), have a mean survival of about a year. Patients with grade 3 or anaplastic gliomas survive for 2-3 years, and those with grade 2 gliomas survive for 10-15 years (Holland, 2001; Louis et al., 2002) .
Genetic analysis of gliomas has identified a variety of cytogenetic abnormalities and molecular genetic changes, and in some cases these findings correlate with clinical grade. One of the earliest known changes in lower grade gliomas is inactivating mutations of TP53 tumour suppressor gene (TSG) as well as overexpression of the platelet-derived growth factor, fibroblast growth factor 2 and their receptors and less commonly allelic loss of chromosome 22q. The progression to grade III astrocytomas is associated with inactivation of the p16-cdk4-pRB pathway as well as allelic loss of 19q. Progression to grade IV gliomas (GBM) is associated with loss of 10q22-25, a region containing the PTEN TSG, and amplification and activating mutations in the epidermal growth factor receptor gene (reviewed in Holland, 2001; Louis et al., 2002) .
Recently, we demonstrated that SLIT2 has tumour suppressor activity and that frequent promoter region hypermethylation of SLIT2 occurs in primary lung, breast and colorectal cancers (Dallol et al., 2002a (Dallol et al., , 2003 . However, in common with other TSGs such as RASSF1A, somatic mutations in SLIT2 appear to be rare (Dammann et al., 2000 (Dammann et al., , 2001 Agathanggelou et al., 2001; Astuti et al., 2001; Burbee et al., 2001; Dreijerink et al., 2001; Lo et al., 2001; Morrissey et al., 2001) . SLIT2 is located at 4p15.2 and encodes the human orthologue of the Drosophila Slit2 protein. The Slit gene family (Slit1, Slit2, Slit3) comprises large extracellular matrix secreted and membrane-associated glycoproteins, which regulate axon guidance, branching and neural migration during development of the central nervous system (Brose et al., 1999) . The Slits are ligands for the repulsive guidance receptors, the robo gene family (robo1, robo2, rig1, robo4) (Stein and Tessier-Lavigne, 2001) . In this report, we demonstrate that SLIT2 is frequently inactivated in glioma cell lines and glioma tumours by promoter region CpG island hypermethylation. The hypermethylation correlates with loss of gene expression and expression is restored after treatment with a demethylating agent.
Materials and methods

Patients and samples
A total of 63 glioma samples, plus seven glioma tumour cell lines (T17, U87-MG, A172, U343, HS683, U373, H4) were analysed. Among the glioma samples, 40 were classified as GBM, all relevant clinical information for these tumours and tumour cell lines was available. The remaining gliomas were collected randomly and consisted of all grades. Five DNA samples from normal brain tissues were also analysed.
Bisulphite modification and methylation analysis
Bisulphite DNA sequencing was performed as described previously (Dallol et al., 2002a) . The SLIT2 putative promoter region from À761 to À212 relative to the translation start site was amplified from cell lines or tumours using the primers Sli2MOD4F (5 0 -GGGAGGTGGGATTGTTTAGATATTT-3 0 ) and primer Sli2MOD4R2 (5 0 -CAAAAACTCCTTAAA CAACTTTAAATCCTAAAA-3 0 ), as we have described previously (Dallol et al., 2002a) . To generate PCR products for combined bisulphite restriction analysis (COBRA) analysis, a semi-nested PCR reaction was performed with primers Sli2MOD4F and Sli2MOD4R (5 0 -ACTAAAACTTCCAA CAACTACTAAAATACAAAAA-3 0 ). For the generation of PCR products for sequencing, 1 : 50 volume of the PCR reaction (with primers Sli2MOD4F and Sli2MOD4R2) was used in a nested PCR reaction with 30 cycles using primer SL2-SP-F (5 0 -AGTTTAGAGTYGTGYGTTTTTAGAAT-3 0 ) and the primer SL2-SP-R (5 0 -CCRATCAAAATAAACTCCR TAAACTAA-3 0 ), where Y is C þ T and R is A þ G. These primers amplify a region where we have found most of the methylated CpGs in the putative SLIT2 promoter to be concentrated. The PCR conditions for both the first and second PCR were 951C for 10 min, followed by 30-40 cycles of 1 min denaturation at 951C, 1 min annealing at 52-541C, and 2 min extension at 741C. The PCR products were concentrated and purified using QIAquick PCR Purification columns (Qiagen). The relevant purified products were either directly sequenced to obtain average methylation levels using ABI BigDye cycle sequencing kit or digested with BstUI restriction enzyme (CG^CG). The ratio of methylated alleles was estimated from the relative peak heights of the G and A peaks at methylated CpG sequences after normalizing the A peak for the average peak height along the entire sequence and subtracting the background G peak. The values obtained were further normalized to the ratio of A and G peak heights in the primer sequence. Specific primers for MSP for p16 and PCR conditions were as reported previously (Herman et al., 1996) .
Cell lines and 5-aza-2
0 -deoxycytidine treatment Glioma cell lines (T17, A172, U343, U373, H4, HS683 and U87-MG) were routinely maintained in BME (Invitrogen) supplemented with 2 mm l-glutamine, 50 mm HEPES and 10% FCS at 371C, 5% CO 2 . The demethylating agent, 5-aza-2 0 -deoxycytidine (5-aza-dC, Sigma), was freshly prepared in ddH 2 O and filter-sterilized. Cells (5-10 Â 10 5 ) were plated in 25 cm 2 flask in DMEM media supplemented with 10% FCS. After 24 h, cells were treated with 10 mm 5-aza-dC. The medium was changed 24 h after treatment and then every 3 days. RNA was prepared at 10 days after treatment using the RNeasy kit (Qiagen) according to the manufacturer's guidelines. SLIT2 expression was detected by RT-PCR using the primers 5 0 -GGTGTCCTCTGTGATGAAGAG-3 0 and 5 0 -GTGTTT AGGAGACACACCTCG-3 0 . The expected product size is 387 bp. Expression of GAPDH was used as a control. The GAPDH primers were described previously (Dallol et al., 2002a) .
Quantitative real-time RT-PCR
SLIT2 mRNA levels in methylated versus unmethylated tumours were quantified using real-time RT-PCR. GAPDH mRNA levels were used for normalization. The relative concentration of SLIT2 or GAPDH was calculated in relation to the standard dilution series and SLIT2 expression levels were normalized for GAPDH values. The following primers were used:
A 100 ng of tumor cDNA was used in each reaction in replicates. In a total volume of 20 ml, 2 ml SYBR Green (LightCycler-DNA Master SYBR Green I, Roche) was mixed with 0.5 mm of each primer and 3-4 mm MgCl 2 for GAPDH and SLIT2, respectively. The following PCR conditions were used: denaturation for 30 s at 941C, followed by 45 cycles with denaturation for 1 s at 941C, annealing for 10 s at 821C for GAPDH or 721C for SLIT2 and elongation for 9 s at 721C.
Growth suppression analysis
The H4 glioma cell line was used for colony-formation assay. Transfection of the H4 cell line was done with Fugene6 reagent (Roche) and used 2 mg of SLIT2 expression construct or vector-only control construct per 25-cm 2 flask containing 5 Â 10 5 cells seeded 24 h before transfection. At 48 h after transfection, 5 Â 10 4 transfected cells were seeded and maintained in DMEM-10% fetal bovine serum supplemented with 200 mg/ml Zeocin (Invitrogen). Surviving colonies were counted 14 days later after staining with crystal violet.
Microsatellite repeat analysis
PCR amplification of the dinucleotide repeat microsatellite marker D4S1546 was performed as described previously (Dallol et al., 2002a) 
Statistical analysis
Comparisons and tests for statistical significance were made by either t-test or Fisher's exact test. P-values of o0.05 were taken as statistically significant.
Results
Epigenetic inactivation of SLIT2 in glioma cell lines
We investigated the methylation status of the CpG island in the promoter region of SLIT2 in seven glioma (Figure 1a ). SLIT2 was found to be methylated in five of seven (71%) glioma cell lines. Direct sequencing of COBRA-positive PCR products revealed that majority of the CpG sites analysed were heavily methylated while COBRA-negative PCR products remained unmethylated (Figure 1c) . Hence, SLIT2 promoter region hypermethylation is a common event in glioma cell lines. We also analysed DNA from five normal brain samples for SLIT2 gene hypermethylation via COBRA and direct sequencing. All five normal brain DNA samples were found to be completely unmethylated at the SLIT2 promoter region CpG island (Figure 2b) .
Expression of SLIT2 was assessed by RT-PCR in the glioma cell lines. Figure 1b , c demonstrates that glioma cell lines methylated or partially methylated for SLIT2 had either complete loss or reduced SLIT2 gene expression, respectively. The treatment of three methylated glioma cell lines (U87-MG, T17, U373) with the demethylating agent 5-aza-dC restored SLIT2 gene expression (Figure 1b) , confirming that promoter hypermethylation is responsible for the loss of expression observed in the methylated cell lines. Furthermore, there was no change in SLIT2 expression in the unmethylated glioma cell line A172 before/after treatment with 5-aza-dC (Figure 1b) .
Epigenetic inactivation of SLIT2 gene in gliomas
To investigate the incidence of promoter region hypermethylation of SLIT2 in vivo, we analysed 63 gliomas. Samples were initially analysed by the COBRA method (Figure 2a) . SLIT2 was found to be methylated in 37 of the 63 cases (59%) analysed. To determine the nature and extent of CpG island hypermethylation, 40 COBRA PCR products were successfully sequenced (Figure 2b) . In COBRA-positive cases, the majority of the CG dinucleotides were heavily methylated in the samples sequenced, while COBRA-negative samples demonstrated no methylation (Figure 2 ). To confirm that the methylation of the SLIT2 promoter region is functionally relevant, we determined SLIT2 expression in seven primary gliomas (for which good-quality RNA was available) using quantitative real-time RT-PCR. Four of the seven gliomas demonstrated SLIT2 promoter region methylation. Quantitative real-time RT-PCR revealed that the four gliomas with SLIT2 methylation expressed markedly lower levels of SLIT2 mRNA than the three gliomas without SLIT2 methylation (Figure 3) .
We also analysed 18 GBM for p16 methylation. None of the gliomas was methylated for p16. Previous reports have demonstrated only low-percentage p16 methylation in gliomas (7%, Yin et al., 2002) . 
Loss of heterozygosity analysis
For 20 gliomas, DNA samples from corresponding blood were available. Loss of heterozygosity analysis, at a microsatellite marker D4S1546 that maps within 100 kb of the SLIT2 gene, demonstrated allele loss in 5% (1/20) of informative cases. All the seven methylated samples demonstrated retention of both the alleles.
We did not find a correlation between patient survival and SLIT2 methylation. However, SLIT2 methylation occurred more frequently in gliomas from patients greater than 50 years of age although this did not quiet reach statistical significance (o50 years of age, 22%; 450 years of age, 63%) (P ¼ 0.055).
Tumour suppressor activity
We have previously shown that exogenous expression of SLIT2 in breast and colorectal tumour cell lines with hypermethylated SLIT2 promoter region and reduced/absent gene expression decreased in vitro Figure 2 SLIT2 promoter region hypermethylation is widespread in gliomas. (a) COBRA analysis of representative set of glioma cases using the BstUI (CG^CG) restriction enzyme. The restriction enzyme MspI (C^CGG) is used as control for the absence of significant amount of unmodified DNA. The fragments sizes range from 18 to 187 bp and a combination of methylated BstUI sites generates different digestion patterns. Tumour T234 is unmethylated, tumours T276, T175 and T205 are methylated. (b) Sequence analysis of SLIT2 promoter region from CpGs 14 to 27 primary glioma cases (T#) and normal brain tissues (N#). Each circle represents a CG dinucleotide, black-filled circles ¼ 490% methylation, grey-filled circles ¼ 50-90% methylation and white circles ¼ unmethylated CG dinucleotides. T234, T24, T26 and N1-5 are unmethylated Figure 3 SLIT2 mRNA expression is downregulated by promoter region hypermethylation in primary glioma samples. SLIT2 expression was detected by quantitative real-time RT-PCR. The same cases were also analysed for the extent of methylation in SLIT2 promoter region. 'U' indicates the unmethylated cases while 'M' indicates the methylated cases. Each circle represents a CG dinucleotide, blackfilled circles ¼ 490% methylation, grey filled circles ¼ 50-90% methylation and white circles ¼ unmethylated CG dinucleotides colony-formation ability. We carried out a similar study in a glioma cell line, wild-type SLIT2 expression plasmid or the pSecTagB empty vector was transfected into the H4 glioma tumour cell line (heavily methylated for SLIT2). Both constructs expressed a zeocin-resistance gene. Transfection with SLIT2 significantly reduced (Po0.0006) the number of zeocin-resistant colonies by 490% compared with transfection with empty vector (Figure 4 ). This effect was consistent through three independent experiments.
Discussion
Methylation of CpG dinucleotides in the promoter regions of TSGs producing transcriptional silencing is a major mechanism of TSG inactivation in many human cancers (Jones, 1999; Costello and Plass 2001; Jones and Baylin, 2002) . Initially, epigenetic silencing of TSGs was reported as an alternative, but minor mechanism of inactivation for TSGs such as RB1 and VHL (Greger et al., 1994; Herman et al., 1994) . However, recently a new class of TSGs has been recognized for which epigenetic silencing is the overwhelming mechanism of inactivation and somatic mutations are rare. This paradigm is exemplified by the RASSF1A 3p21.3 TSG, which is methylated in a wide range of human cancers (Dammann et al., 2000; Agathanggelou et al., 2001; Astuti et al., 2001; Burbee et al., 2001; Dreijerink et al., 2001; Lo et al., 2001; Morrissey et al., 2001) .
Recently we identified frequent promoter region hypermethylation of SLIT2 in lung, breast and colorectal cancers (Dallol et al., 2002a (Dallol et al., , 2003 . SLIT2 maps to 4p15.2 and encodes a human orthologue of the Drosophila Slit protein, a secreted glycoprotein, which regulates axon guidance, branching and neural migration during development of the central nervous system (Brose et al., 1999) . Slit exerts its effect as a diffusible chemorepellent via its receptor Roundabout (Robo) (Stein and Tessier-Lavigne, 2001 ).
Previously we (a) identified frequent SLIT2 promoter region hypermethylation in non-small-cell lung cancers, small-cell lung cancers, breast and colorectal tumours, (b) in lung and breast cancer, SLIT2 mutations were not detected despite frequent promoter methylation (similar to RASSF1A), (c) demonstrated that promoter region hypermethylation is associated with reversible transcriptional silencing, (d) determined that restoration of SLIT2 expression suppressed tumour growth in in vitro studies, and (e) conditioned media from SLIT2-transfected COS-7 cells induced apoptosis in a tumour cell line (Dallol et al., 2002a (Dallol et al., , 2003 . Thus, having established SLIT2 as a lung, breast and colorectal cancer suppressor gene, we have now identified frequent SLIT2 hypermethylation in glioma cell lines (71%) and glioma tumours (59%). Direct sequencing of the COBRApositive cases revealed that the majority of the CG dincleotides were intensely methylated. Glioma cell lines and tumours with SLIT2 methylation had reduced SLIT2 expression compared to unmethylated cell lines and tumours. In glioma cell lines, the loss of SLIT2 expression could be restored after treatment with a demethylating agent. 4p15.2 loss is not a frequent event in gliomas (Burton et al., 2002) and this fits in well with the present data, demonstrating 5% allelic loss at a 4p15.2 microsatellite marker (D4S1546) located within 100 kb of the SLIT2 gene. Majority of the SLIT2 methylated and unmethylated tumours retained both alleles at D4S1546. This scenario is similar to RASSF1A methylation in medulloblastomas, where there was no evidence of RASSF1A inactivation by allelic loss or somatic mutations in tumour samples with or without RASSF1A methylation (Lusher et al., 2002) . Moreover; exogenous expression of SLIT2 in a glioma cell line, demonstrating heavy methylation of SLIT2, decreased in vitro colony formation.
We did not find any association between SLIT2 methylation and clinical parameters, apart from that the patients 450 years of age demonstrated SLIT2 methylation more frequently than patients o50 years. However, this did not reach statistical significance, larger studies are required to determine any association with age.
Slit protein binds to the roundabout receptor and acts as a midline repellent to guide axonal development during embryogenesis (Rajagopalan et al., 2000; Simpson et al., 2000; Wong et al., 2001) . In mice, Robo1 inactivation produces delayed lung maturation and bronchial hyperplasia (Xian et al., 2001 ) and we have demonstrated de novo ROBO1 promoter methylation in 19% primary invasive breast carcinomas, 18% primary clear cell RCC and in 19% of colorectal carcinomas although somatic mutations were not identified (Dallol et al., 2002b (Dallol et al., , 2003 . Slit proteins function as secreted chemorepellants, so that 
